# US 2017/0285044 A1 · Methods for predicting and improving the survival of gastric cancer patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0285044 A1
- Document ID: US20170285044A1
- Status: Published application
- Kind: A1
- Application number: 15/623,011
- Filed: 2017-06-14
- Published: 2017-10-05
- Earliest claimed: 2011-04-04
- Assignees: Pierian Holdings, Inc.
- Applicants: Pierian Holdings, Inc.
- Inventors: Phillip Kim; Sharat Singh
- Web page: https://patentgrep.com/patent/US20170285044A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 31/517: ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- G01N 33/5753: of the stomach or small intestine
- G01N 2333/71: for growth factors; for growth regulators
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N 2800/54: Determining the risk of relapse
- G01N 2800/56: Staging of a disease; Further complications associated with the disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides assays and methods for predicting the post-operative survival of a subject having an early stage gastric cancer after tumor surgery. The present invention also provides methods for treating a subject having an early stage gastric cancer by administering a combination therapy tailored to the signal transduction biomarkers that are activated in the cancer. In particular embodiments, the methods of the invention rely on the detection of the activation state or level of a specific combination of signal transducer analytes in a cancer cell obtained from the subject. Thus, the methods of the invention are particularly useful for predicting the survival or prognosis of a subject having an early stage gastric cancer and for guiding both pre- and post-operative treatment decisions by identifying subjects who would benefit from combination therapy as opposed to monotherapy.

## Claims

### Claim 1

A method for treating a subject having stage I or II gastric cancer, the method comprising:
administering a combination therapy comprising a cMET inhibitor and a HER1 inhibitor to the subject, wherein cMET and HER1 are coactivated in the stage I or II gastric cancer.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject has worse survival and/or poorer prognosis compared to stage I or II gastric cancer subjects with cMet activation in the absence of HER1 activation.

### Claim 3 (depends on 1)

The method of claim 1, wherein the combination therapy is administered to the subject as primary therapy.

### Claim 4 (depends on 1)

The method of claim 1, wherein the combination therapy is administered to the subject as adjuvant therapy after tumor surgery.

### Claim 5 (depends on 1)

The method of claim 1, wherein HER2 is not activated in the stage I or II gastric cancer.

### Claim 6 (depends on 5)

The method of claim 5, wherein the subject has worse survival and/or poorer prognosis compared to stage I or II gastric cancer subjects with cMet activation in the absence of HER1 and/or HER2 activation.

### Claim 7 (depends on 1)

The method of claim 1, wherein HER3 is activated in the stage I or II gastric cancer.

### Claim 8 (depends on 7)

The method of claim 7, wherein the subject has worse survival and/or poorer prognosis compared to stage I or II gastric cancer subjects with cMET activation in the absence of HER1, HER2, and/or HER3 activation.

### Claim 9 (depends on 1)

The method of claim 1, wherein the cMET inhibitor is selected from the group consisting of AMG102, MetMAb, ARQ197, JNJ-38877605, PF-2341066, PF-04217903, SGX523, GSK1363089/XL880, XL184, MGCD265, MK-2461, PHA-665752, and combinations thereof.

### Claim 10 (depends on 1)

The method of claim 1, wherein the HER1 inhibitor is selected from the group consisting of erlotinib, lapatinib, gefitinib, BIBW-2992, and combinations thereof.

### Claim 11 (depends on 1)

The method of claim 1, wherein the presence or level of activation of cMET and HER1 is determined in a cancer cell obtained from the subject.

### Claim 12 (depends on 11)

The method of claim 11, wherein the cancer cell is selected from the group consisting of a primary tumor cell, a circulating tumor cell (CTC) , an ascites tumor cell (ATC), and combinations thereof.

### Claim 13 (depends on 11)

The method of claim 11, wherein the presence or level of activation of cMET and HER1 is determined with a Collabotrative Enzyme Enhanced Reactive Immunoassay (CEER™).
